Browse > Article
http://dx.doi.org/10.14348/molcells.2017.0025

Up-Regulation of RANK Expression via ERK1/2 by Insulin Contributes to the Enhancement of Osteoclast Differentiation  

Oh, Ju Hee (Department of Medical Science, College of Medical Sciences, Soonchunhyang University)
Lee, Na Kyung (Department of Medical Science, College of Medical Sciences, Soonchunhyang University)
Publication Information
Molecules and Cells / v.40, no.5, 2017 , pp. 371-377 More about this Journal
Abstract
Despite the importance of the receptor activator of nuclear factor (NF)-kappaB ligand (RANKL)-RANK signaling mechanisms on osteoclast differentiation, little has been studied on how RANK expression is regulated or what regulates its expression during osteoclastogenesis. We show here that insulin signaling increases RANK expression, thus enhancing osteoclast differentiation by RANKL. Insulin stimulation induced RANK gene expression in time- and dose-dependent manners and insulin receptor shRNA completely abolished RANK expression induced by insulin in bone marrow-derived monocyte/macrophage cells (BMMs). Moreover, the addition of insulin in the presence of RANKL promoted RANK expression. The ability of insulin to regulate RANK expression depends on extracellular signal-regulated kinase 1/2 (ERK1/2) since only PD98059, an ERK1/2 inhibitor, specifically inhibited its expression by insulin. However, the RANK expression by RANKL was blocked by all three mitogen-activated protein (MAP) kinases inhibitors. The activation of RANK increased differentiation of BMMs into tartrate-resistant acid phosphatase-positive ($TRAP^+$) osteoclasts as well as the expression of dendritic cell-specific transmembrane protein (DC-STAMP) and d2 isoform of vacuolar ($H^+$) ATPase (v-ATPase) Vo domain (Atp6v0d2), genes critical for osteoclastic cell-cell fusion. Collectively, these results suggest that insulin induces RANK expression via ERK1/2, which contributes to the enhancement of osteoclast differentiation.
Keywords
ERK1/2; insulin; osteoclastogenesis; RANK;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Boyle, W.J., Simonet, W.S., and Lacey, D.L. (2003). Osteoclast differentiation and activation. Nature 423, 337-342.   DOI
2 Choi, H.K., Kang, H.R., Jung, E., Kim, T.E., Lin, J.J., and Lee, S.Y. (2013). Early estrogen-induced gene 1, a novel RANK signaling component, is essential for osteoclastogenesis. Cell Res. 23, 524-536.   DOI
3 Dougall, W.C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M.E., Maliszewski, C.R., et al. (1999). RANK is essential for osteoclast and lymph node development. Genes. Dev. 13, 2412-2424.   DOI
4 Erbagci, A.B., Araz, M., Erbagci, A., Tarakcioglu, M., and Namiduru, E.S. (2002). Serum prolidase activity as a marker of osteoporosis in type 2 diabetes mellitus. Clin. Biochem. 35, 263-268.   DOI
5 Ferron, M., Wei, J., Yoshizawa, T., Del Fattore, A., DePinho, R.A., Teti, A., Ducy, P., and Karsenty, G. (2010). Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142, 296-308.   DOI
6 Fleischmann, A., Hafezi, F., Elliott, C., Reme, C.E., Ruther, U., and Wagner, E.F. (2000). Fra-1 replaces c-Fos-dependent functions in mice. Genes. Dev. 14, 2695-2700.   DOI
7 Fulzele, K., DiGirolamo, D.J., Liu, Z., Xu, J., Messina, J.L., and Clemens, T.L. (2007). Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J. Biol. Chem. 282, 25649-25658.   DOI
8 Fulzele, K., Riddle, R.C., DiGirolamo, D.J., Cao, X., Wan, C., Chen, D., Faugere, M.C., Aja, S., Hussain, M.A., Bruning, J.C., et al. (2010). Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142, 309-319.   DOI
9 Harada, S., and Rodan, G.A. (2003). Control of osteoblast function and regulation of bone mass. Nature 423, 349-355.   DOI
10 Hemingway, F., Taylor, R., Knowles, H.J., Athanasou, N.A. (2011). RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone 48, 938-944.   DOI
11 Kim, K., Lee, S.H., Ha Kim, J., Choi, Y., and Kim, N. (2008). NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol. Endocrinol. 22, 176-185.   DOI
12 Hsu, H., Lacey, D.L., Dunstan, C.R., Solovyev, I., Colombero, A., Timms, E., Tan, H.L., Elliott, G., Kelley, M.J., Sarosi, I., et al. (1999). Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. U.S.A. 96, 3540-3545.   DOI
13 Itonaga, I., Sabokbar, A., Sun, S.G., et al. (2004). Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. Bone 34, 57-64.   DOI
14 Isaia, G.C., Ardissone, P., Di Stefano, M., Ferrari, D., Martina, V., Porta, M., Tagliabue, M., and Molinatti, G.M. (1999). Bone metabolism in type 2 diabetes mellitus. Acta. Diabetol. 36, 35-38.   DOI
15 Kemink, S.A., Hermus, A.R., Swinkels, L.M., Lutterman, J.A., and Smals, A.G. (2000). Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J. Endocrinol. Invest. 23, 295-303.   DOI
16 Kim, H.S. and Lee, N.K. (2014). Gene expression profiling in osteoclast precursors by insulin using microarray analysis. Mol. Cells 37, 827-832.   DOI
17 Kudo, O., Sabokbar, A., Pocock, A., Itonaga, I., Fujikawa, Y., Athanasou, N.A. (2003). Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32,1-7.   DOI
18 Lacey, D.L., Timms, E., Tan, H.L., Kelley, M.J., Dunstan, C.R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.   DOI
19 Lee, N.K. (2010). Molecular Understanding of Osteoclast Differentiation and Physiology. EnM. 25, 264-269.
20 Lee, J.Y., and Lee, N.K. (2014) Up-regulation of cyclinD1 and Bcl2A1 by insulin is involved in osteoclast proliferation. Life sci. 114, 57-61.   DOI
21 Lee, S.H., Rho, J., Jeong, D., Sul, J.Y., Kim, T., Kim, N., Kang, J.S., Miyamoto, T., Suda, T., Lee, S.K., et al. (2006). v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat. Med. 12, 1403-1409.   DOI
22 Ogata, N., Chikazu, D., Kubota, N., Terauchi, Y., Tobe, K., Azuma, Y., Ohta, T., Kadowaki, T., Nakamura, K., and Kawaguchi, H. (2000). Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J. Clin. Invest. 105, 935-943.   DOI
23 Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998). Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597-3602.   DOI
24 Li, J., Sarosi, I., Yan, X.Q., Morony, S., Capparelli, C., Tan, H.L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000). RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. U.S.A. 97, 1566-1571.   DOI
25 Luchin, A., Suchting, S., Merson, T., Rosol, T.J., Hume, D.A., Cassady, A.I., and Ostrowski, M.C. (2001). Genetic and physical interactions between Microphthalmia transcription factor and PU.1 are necessary for osteoclast gene expression and differentiation. J. Biol. Chem. 276, 36703-36710.   DOI
26 Manolagas, S.C. (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21, 115-137.
27 Matsuo, K., Owens, J.M., Tonko, M., Elliott, C., Chambers, T.J., and Wagner, E.F. (2000). Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat. Genet. 24, 184-187.   DOI
28 Oh, J.H., Lee, J.Y., Joung, S.H., Oh, Y.T., Kim, H.S., and Lee, N.K. (2015a). Insulin enhances RANKL-induced osteoclastogenesis via ERK1/2 activation and induction of NFATc1 and Atp6v0d2. Cell. Signal. 27, 2325-2331.   DOI
29 Oh, J.H., Lee, J.Y., Park, J.H., No, J.H., and Lee, N.K. (2015b). Obatoclax regulates the proliferation and fusion of osteoclast precursors through the inhibition of ERK activation by RANKL. Mol. Cells 38, 279-284.   DOI
30 Rodan, G.A. and Martin, T.J. (2000). Therapeutic approaches to bone diseases. Science 289, 1508-1514.   DOI
31 Thrailkill, K.M., Lumpkin, C.K., Jr., Bunn, R.C., Kemp, S.F., and Fowlkes, J.L. (2005). Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am. J. Physiol. Endocrinol. Metab. 289, E735-745.   DOI
32 Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M.T., and Martin, T.J. (1999). Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345-357.   DOI
33 Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J., et al. (2002). Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889-901.   DOI
34 Teitelbaum, S.L. (2000). Bone resorption by osteoclasts. Science 289, 1504-1508.   DOI
35 Vestergaard, P. (2007). Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a metaanalysis. Osteoporos. Int. 18, 427-444.   DOI
36 Yagi, M., Miyamoto, T., Sawatani, Y., Iwamoto, K., Hosogane, N., Fujita, N., Morita, K., Ninomiya, K., Suzuki, T., Miyamoto, K., et al. (2005). DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J. Exp. Med. 202, 345-351.   DOI
37 Yang, J., Zhang, X., Wang, W., and Liu, J. (2010). Insulin stimulates osteoblast proliferation and differentiation through ERK and PI3K in MG-63 cells. Cell. Biochem. Funct. 28, 334-341.   DOI